--- deleted post (at posters request)
Do you think of things like this?
Biotome, founded in 2017 by Professor Samuel Lundin, Dr Alma Fulurija and Nobel Laureate Professor Barry Marshall, is developing next-generation antibody tests (serology tests) based on precision
wholesaleinvestor.com.au
".....
Their diagnostics involve small pieces of proteins (i.e. peptides) instead of whole proteins as analysis markers. This is a fundamental advantage compared to conventional serology, as it allows the full use of the high resolution of the immune system, resulting in
higher precision and lower cost compared to conventional techniques. An added advantage is that the markers of Biotome’s tests are
patentable, unlike conventional protein markers.
Biotome has three diagnostic projects in the pipeline, each addressing large markets. The most progressed project,
HelitopeTM, is a simple
blood test for stomach cancer risk. The two other projects are focused on developing an antibody-test for COVID-19 (
CovitopeTM) as well as a test for the risk of pre-eclampsia development.
....."